secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001570562-26-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus Q4 2025 prelim rev $88.6-90.6M (+12-15%); 2026 rev guide $327-337M; targets profitability
--------------------------------------------------------------------------------

- Preliminary Q4 2025 net revenue $88.6M-$90.6M, 12-15% YoY growth; positive non-GAAP op income $5M-$7M.
- FY 2025 net revenue $295.5M-$297.5M, 11-12% YoY; Evolysse HA gels contributed ~8% of total revenue.
- 2026 guidance: net revenue $327M-$337M (11-13% growth); sustainable annual profitability commencing in 2026.
- Updated 2028 long-term outlook: net revenue $450M-$500M (15-19% CAGR); non-GAAP op margin 13-15%.
- Cash $53M at Dec 31, 2025, up from $43.5M at Sep 30, 2025, reflecting strong sales and expense management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056226000003/0001570562-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056226000003/eols-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001570562-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer